Wall Street analysts expect Vericel Co. (NASDAQ:VCEL) to report earnings of ($0.06) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Vericel’s earnings, with estimates ranging from ($0.07) to ($0.03). Vericel reported earnings per share of ($0.18) in the same quarter last year, which suggests a positive year over year growth rate of 66.7%. The company is expected to announce its next quarterly earnings results on Wednesday, August 4th.
According to Zacks, analysts expect that Vericel will report full year earnings of $0.05 per share for the current fiscal year, with EPS estimates ranging from $0.00 to $0.07. For the next fiscal year, analysts anticipate that the business will post earnings of $0.46 per share, with EPS estimates ranging from $0.22 to $0.57. Zacks’ EPS averages are an average based on a survey of research analysts that cover Vericel.
Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, May 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). Vericel had a net margin of 3.24% and a return on equity of 3.45%. The business had revenue of $34.57 million for the quarter, compared to the consensus estimate of $32.04 million. During the same period in the previous year, the firm earned ($0.10) EPS. The company’s revenue was up 29.6% compared to the same quarter last year.
In other news, Director Paul K. Wotton sold 5,000 shares of the stock in a transaction that occurred on Friday, May 14th. The stock was sold at an average price of $50.52, for a total transaction of $252,600.00. Following the completion of the transaction, the director now directly owns 26,602 shares in the company, valued at approximately $1,343,933.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Paul K. Wotton sold 13,448 shares of the stock in a transaction on Tuesday, May 11th. The stock was sold at an average price of $50.11, for a total value of $673,879.28. Following the completion of the sale, the director now directly owns 21,000 shares in the company, valued at $1,052,310. The disclosure for this sale can be found here. Insiders sold a total of 116,372 shares of company stock worth $6,208,573 over the last ninety days. Corporate insiders own 4.60% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Sowell Financial Services LLC acquired a new stake in shares of Vericel during the 1st quarter worth approximately $29,000. Captrust Financial Advisors acquired a new stake in Vericel in the first quarter valued at $36,000. Nisa Investment Advisors LLC increased its position in Vericel by 302.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,595 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,950 shares during the period. E Fund Management Co. Ltd. bought a new position in Vericel during the first quarter worth about $165,000. Finally, Lazard Asset Management LLC increased its position in Vericel by 53.7% during the fourth quarter. Lazard Asset Management LLC now owns 3,460 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 1,209 shares during the period.
Shares of VCEL traded up $0.01 on Friday, hitting $57.67. 2,508 shares of the stock traded hands, compared to its average volume of 755,126. The firm has a 50 day simple moving average of $55.87. The stock has a market cap of $2.67 billion, a P/E ratio of 720.84 and a beta of 2.10. Vericel has a one year low of $12.82 and a one year high of $64.89.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.